Atara Biotherapeutics (NASDAQ:ATRA) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a research note released on Wednesday. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a neutral rating on shares of Atara Biotherapeutics in a research report on Wednesday, May 22nd.

Atara Biotherapeutics Price Performance

NASDAQ ATRA opened at $8.50 on Wednesday. Atara Biotherapeutics has a fifty-two week low of $4.96 and a fifty-two week high of $63.38. The business has a fifty day moving average price of $14.06 and a two-hundred day moving average price of $16.14. The stock has a market capitalization of $40.97 million, a PE ratio of -0.16 and a beta of 0.54.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($5.75) earnings per share for the quarter, beating the consensus estimate of ($9.25) by $3.50. The business had revenue of $27.36 million for the quarter, compared to analyst estimates of $27.00 million. Atara Biotherapeutics had a negative return on equity of 783.31% and a negative net margin of 671.70%. As a group, sell-side analysts expect that Atara Biotherapeutics will post -15.75 earnings per share for the current year.

Insider Activity at Atara Biotherapeutics

In related news, CEO Pascal Touchon sold 3,260 shares of the stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $15.50, for a total value of $50,530.00. Following the completion of the sale, the chief executive officer now directly owns 73,165 shares in the company, valued at $1,134,057.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Atara Biotherapeutics news, CEO Pascal Touchon sold 3,260 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $15.50, for a total transaction of $50,530.00. Following the completion of the transaction, the chief executive officer now owns 73,165 shares in the company, valued at approximately $1,134,057.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Anhco Nguyen sold 1,715 shares of the company’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $15.50, for a total transaction of $26,582.50. Following the completion of the sale, the executive vice president now directly owns 35,939 shares in the company, valued at $557,054.50. The disclosure for this sale can be found here. Insiders sold a total of 6,120 shares of company stock worth $94,860 in the last quarter. 3.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ATRA. Redmile Group LLC grew its holdings in Atara Biotherapeutics by 1.7% in the first quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock worth $6,429,000 after purchasing an additional 156,863 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Atara Biotherapeutics by 8,916.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock valued at $3,442,000 after buying an additional 4,903,159 shares during the period. Delap Wealth Advisory LLC bought a new stake in Atara Biotherapeutics in the 1st quarter valued at about $29,000. Acadian Asset Management LLC raised its stake in Atara Biotherapeutics by 49.5% during the 1st quarter. Acadian Asset Management LLC now owns 2,638,687 shares of the biotechnology company’s stock worth $1,830,000 after buying an additional 873,133 shares during the period. Finally, BNP Paribas Financial Markets boosted its holdings in Atara Biotherapeutics by 29.3% in the first quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock worth $266,000 after acquiring an additional 86,842 shares in the last quarter. 70.90% of the stock is owned by institutional investors and hedge funds.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.